CurrentBlue Cross Blue Shield - NevadaPolicy N/A

Local Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Defines clinical appropriateness, contraindications, required documentation, timing, and coding guidance for use of locally delivered chemotherapeutic/antimicrobial agents (LDCA/LDAA) as adjunctive therapy in periodontal disease management for dental benefits.

Policy Summary

PayerBlue Cross Blue Shield - Nevada

PolicyLocal Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Policy CodePolicy N/A

Change TypeRevised (no material clinical changes noted)

Effective DateJan 1, 2025

Next Review DateN/A

Key ActionObtain and retain a current (within 12 months), dated, post-periodontal maintenance and/or post-periodontal surgery 6-point periodontal charting to support LDCA/LDAA use.

SourceLink

POLICY UPDATE CHANGES

Policy status marked Revised; publish date 01/01/2025 with last review date 10/28/2024.

>=5 mmMinimum pocket depth for consideration

6-24Post-treatment waiting interval (weeks)

12Charting recency (months)

Coverage Summary

Scope: This coverage criteria addresses the use of local delivery of chemotherapeutic/antimicrobial agents (LDCA/LDAA) as adjunctive subgingival therapy in periodontal disease management. Subject: Local delivery of chemotherapeutic/antimicrobial agents for periodontal disease. Coverage stance: mixed — the plan considers LDCA/LDAA appropriate in limited, specific circumstances and not routinely for generalized disease. Status: CURRENT (Revised). Effective date: 01/01/2025; Last review date: 10/28/2024.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Summary: LDCA/LDAA are considered adjunctive treatment for isolated refractory periodontal pockets after completion of definitive non-surgical and/or surgical therapy (for example, scaling and root planing) or when identified during periodontal maintenance. The policy emphasizes that scaling and root planing is the standard of care and that most diseased sites will respond to non-surgical therapy; localized delivery is limited to defined refractory/isolated sites meeting the policy's specific clinical thresholds.